Ari Feuer helps clients assess and adapt to healthcare policies in areas such as Medicaid, the 340B drug discount program, healthcare quality, the Inflation Reduction Act, and market dynamics for rare disease products.

Before joining Avalere, Ari held several internship and research positions. At UnitedHealth Group, Ari conducted quantitative and qualitative research into Medicare Advantage, low-value care, health equity, and prescription drug pricing for published deliverables and academic manuscripts. At the Association for Community Affiliated Plans, he analyzed primary research, state Medicaid contracts, and federal regulations to assist more than 70 safety net health plans. Ari has also worked on multiple Maryland legislative campaigns specializing in health insurance policy.

Ari holds a bachelor’s degree in public health from The George Washington University.

Authored Content

Manufacturers should reevaluate CMS engagement strategies as soon as possible to maximize the opportunity to influence the IPAY 2026 Medicare negotiations.

Some federal grant recipients use 340B program eligibility to expand their reach and services provided to a wide range of patient populations.

CMS selected 10 Part D drugs for the first year of negotiation. Stakeholders should consider engagement opportunities and evaluate broader therapeutic dynamics.

Comments on initial negotiation guidance significantly shaped the revised guidance, underscoring the importance of stakeholder engagement in IRA implementation.

Recently released guidance and a second draft Negotiation Data Elements ICR introduce several opportunities for patients and caregivers to shape negotiation.

The revised guidance contains significant changes to the initial guidance released in March, but important outstanding questions remain.

The IRA will increase health plans’ financial risk, elevating the importance of Medicare Part D risk adjustment.

Drug manufacturers, covered entities, and other 340B stakeholders have shown increased interest in 340B duplicate discounts.

Providers and pharmacies are two critical stakeholders that should prepare their own IRA strategies to adequately react to a changing landscape.

Plans preparing MA-PD and PDP bids for Plan Year 2025 should consider how Part D redesign will affect enrollee costs, plan payment, and market dynamics.

Manufacturers may find significant gaps between their existing evidence and the negotiation data elements that CMS will evaluate during the negotiation process.

IRA inflation rebates and drug price negotiation will impact drug launch prices in Medicare, with spillover effects in the Medicaid and commercial markets.

As CMS clarifies evidence requirements for drug price negotiations, manufacturers should prepare their strategies for asset development and on-market products.